Long Build Up Seen In Opko Health Inc (NYSE:OPK)
On Tuesday, Opko Health Inc (NYSE:OPK) experienced some unusual options-trading Stock traders bought 24,702 call-options on the company. This is a representation of a 357% rise in comparison to the average daily-volume of 5,400 call-options. In separate company news, Phillip Md Et Al Frost, the company’s Director purchased 7,000 shares of the company’s stock on the open-market in the transaction that was dated 11 October. This stock was bought at an average-price of $10.03/share and the total value of the transaction was $70,210.00.
Numerous analysts have commented on the Opko Health Inc (NYSE:OPK) stock recently. Barrington Research analysts’ reiterated their “buy” rating on the company shares on 9 September. Separately, Jefferies Group analysts raised their PT on Opko Health Inc (NYSE:OPK) shares from $9.00 to $10.00 on 9 September and have now assigned a “buy” rating on Opko Health Inc (NYSE:OPK)’s stock.
In Tuesday’s trading, Opko Health Inc (NYSE:OPK) rose by 12.56%. The opening price of the shares was $11.04, which climbed to an intraday high of $12.84 and dipped to a close of $12.28. Approximately 19.14 million shares were traded on Tuesday while an average volume of 4.73 million shares were traded over a 30 day period. The 52-week low of Opko Health Inc (NYSE:OPK) shares is $4.20 and its 52-week high is $12.84. Opko Health Inc (NYSE:OPK) has a market capitalization of $4.96 billion.
About the company
Opko Health Inc (NYSE:OPK) is a multinational pharma & diagnostics company. It is involved in the development of a variety of solutions. These solutions will be used in diagnosing, treating and preventing numerous conditions such as molecular-diagnostics tests, point of care tests, vaccines and pharmaceuticals. Opko Health Inc (NYSE:OPK)’s lead-program is the molecular-diagnostics platform that is used in the development & commercialization of various blood-based tests for different conditions.